Auswahl der wissenschaftlichen Literatur zum Thema „Stambomycine“
Geben Sie eine Quelle nach APA, MLA, Chicago, Harvard und anderen Zitierweisen an
Inhaltsverzeichnis
Machen Sie sich mit den Listen der aktuellen Artikel, Bücher, Dissertationen, Berichten und anderer wissenschaftlichen Quellen zum Thema "Stambomycine" bekannt.
Neben jedem Werk im Literaturverzeichnis ist die Option "Zur Bibliographie hinzufügen" verfügbar. Nutzen Sie sie, wird Ihre bibliographische Angabe des gewählten Werkes nach der nötigen Zitierweise (APA, MLA, Harvard, Chicago, Vancouver usw.) automatisch gestaltet.
Sie können auch den vollen Text der wissenschaftlichen Publikation im PDF-Format herunterladen und eine Online-Annotation der Arbeit lesen, wenn die relevanten Parameter in den Metadaten verfügbar sind.
Zeitschriftenartikel zum Thema "Stambomycine"
Wang, Yongchen, Venkaiah Chintalapudi, Haraldur G. Gudmundsson, Gregory L. Challis und Edward A. Anderson. „Synthesis of the C50 diastereomers of the C33–C51 fragment of stambomycin D“. Organic Chemistry Frontiers 9, Nr. 2 (2022): 445–49. http://dx.doi.org/10.1039/d1qo01635k.
Der volle Inhalt der QuelleSong, Lijiang, Luisa Laureti, Christophe Corre, Pierre Leblond, Bertrand Aigle und Gregory L. Challis. „Cytochrome P450-mediated hydroxylation is required for polyketide macrolactonization in stambomycin biosynthesis“. Journal of Antibiotics 67, Nr. 1 (13.11.2013): 71–76. http://dx.doi.org/10.1038/ja.2013.119.
Der volle Inhalt der QuelleSu, Li, Laurence Hôtel, Cédric Paris, Clara Chepkirui, Alexander O. Brachmann, Jörn Piel, Christophe Jacob, Bertrand Aigle und Kira J. Weissman. „Engineering the stambomycin modular polyketide synthase yields 37-membered mini-stambomycins“. Nature Communications 13, Nr. 1 (26.01.2022). http://dx.doi.org/10.1038/s41467-022-27955-z.
Der volle Inhalt der QuelleSu, Li, Laurence Hôtel, Cédric Paris, Clara Chepkirui, Alexander O. Brachmann, Jörn Piel, Christophe Jacob, Bertrand Aigle und Kira J. Weissman. „Author Correction: Engineering the stambomycin modular polyketide synthase yields 37-membered mini-stambomycins“. Nature Communications 13, Nr. 1 (06.10.2022). http://dx.doi.org/10.1038/s41467-022-33524-1.
Der volle Inhalt der QuelleLim, Jieyan, Venkaiah Chintalapudi, Haraldur G. Gudmundsson, Minh Tran, Alice Bernasconi, Araceli Blanco, Lijiang Song, Gregory L. Challis und Edward A. Anderson. „Synthesis of the C1–C27 Fragment of Stambomycin D Validates Modular Polyketide Synthase-Based Stereochemical Assignments“. Organic Letters, 08.09.2021. http://dx.doi.org/10.1021/acs.orglett.1c02650.
Der volle Inhalt der QuelleDissertationen zum Thema "Stambomycine"
Su, Li. „Generation of analogues of the anti-tumor polyketide stambomycins by genetic engineering and allied approaches“. Electronic Thesis or Diss., Université de Lorraine, 2021. http://www.theses.fr/2021LORR0081.
Der volle Inhalt der QuelleThe polyketide secondary metabolites of bacteria are a rich source of bioactive agents, with notable applications in anti-infective and anti-cancer therapy. However, their structures often need to be optimized in order to tailor their therapeutic and biophysical properties. The 51-membered macrolide stambomycins, among the largest of known polyketides, were recently discovered by genome mining in Streptomyces ambofaciens ATCC23877, and notably exhibit promising anti-cancer activity. The family encompasses six members which differ from each other in the alkyl functionality at C-26, due to the alternative choice of extender units by an exceptional acyl transferase domain (AT12) of the modular polyketide synthase (PKS) responsible for synthesizing the stambomycin core. Given their enormous size of the stambomycins and the intrinsic promiscuity of AT12, there is substantial interest in accessing ring-contracted and C-26 substituted derivatives of this compounds which might retain the bioactivity of the parental structures, or exhibit improved or even new properties. In this work, we have leveraged our current understanding of modular PKS systems to internally contract the stambomycin assembly line, leading to the successful generation, albeit at low yield, of target smaller derivatives (37-membered ‘mini-stambomycins’). By careful analysis, we could identify multiple factors contributing to the low titers, information which should inform future engineering strategies. Furthermore, using a mutasynthesis strategy, we were able to exploit the broad specificity of the AT12 domain to create 6 novel C-26 substituted stambomycin analogues. Finally, we unexpectedly identified three series of novel desferrioxamine siderophores produced by S. ambofaciens. As a number of key metabolites generated in this work have potential interest for therapeutic applications, they will be targeted for purification, structural characterization and biological evaluation